This finding was confirmed by the increase in the intracellular level of the P-glycoprotein substrate doxorubicin, which is a commonly used anti-cancer agent in clinic, in R-HepG2 cells treated with 0.6 μM and 0.8 μM Pa-PDT at 2 h (Figure 4B). This evidence concerns the gene ABCB1 and cancer.